tbuckley/cabot-search huggingface dataset:
MAIT Cell–Mediated Immune Mechanisms of Dialysis-Induced Peritoneal Fibrosis and Therapeutic Targeting
Authors: Yuxiang Sun, Qiang Huang, Juan Sun, Hu Zhou, Dandan Guo, Long Peng, Hongchun Lin, Canming Li, Hongli Shang, Tongtong Wang, Yanxu Chen, Yong Huang, Cheng Hu, Zhaoyong Hu, Yan Lu, Hui Peng
Journal: Journal of the American Society of Nephrology (2025)

Background: Peritoneal fibrosis is a serious complication of long-term peritoneal dialysis (PD) and abdominal surgeries, yet effective treatments remain elusive. Given the known roles of mucosal-associated invariant T (MAIT) cells in immune responses and fibrotic diseases, we investigated their involvement in PD-induced peritoneal fibrosis to identify potential therapeutic targets. Methods: We employed single-cell RNA sequencing (scRNA-seq) and flow cytometry to characterize the activation and function of peritoneal MAIT cells in patients undergoing long-term PD. Our investigation focused on the molecular pathways activated by these cells, particularly the MHC class I–related protein 1 (MR1)-mediated interaction with mesothelial cells and subsequent activation of the mTORC1 signaling pathway. We further assessed the impact of inhibiting MAIT cells on fibrogenesis using both in vitro models and Mr1 knockout mice. Results: Our study revealed that long-term PD significantly enhanced the activation of MAIT cells, particularly the pro-inflammatory MAIT17 subtype. These activated cells contributed to peritoneal fibrogenesis by binding to the MR1 receptor on mesothelial cells, which triggered hyperglycolysis through the mTORC1 pathway, ultimately leading to fibrogenesis. Notably, we demonstrated that blocking the MR1-MAIT interaction, either through genetic knockout or pharmacological inhibition with acetyl-6-formylpterin (Ac-6-FP), effectively mitigated fibrosis. Conclusions: This study identified MAIT cells as crucial drivers of PD-induced peritoneal fibrosis.
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
Authors: Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum, Deborah D Glass, Jee Hyun Park, Michele Donato, David S Siegel, Tania C Felizardo, Daniel H Fowler
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (T CM ) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context. Methods The clinical trial ( NCT04176380 ) evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma (RRMM). Results From December 2020 to December 2022, 14 patients with RRMM received a median of three RAPA-201 infusions (median dose, 80×10 6 cells). RAPA-201 drug products (DPs) were: polyclonal; enriched for T CM cells; reduced for immune checkpoint expression, including PD1, CD73, and LAIR1; and preferentially secreted Th1 cytokines. The median chemotherapy dose administered per cycle was 1,817 mg total for cyclophosphamide (range, 1,100–2,200) and 2.35 mg/M 2 for pentostatin (range, 0–16). Nine of 14 patients (64%) achieved disease remission, with eight partial responses and one stringent complete response. Median progression-free survival was 6.0 months (range, 2.1 to&gt;16.8 months). There were no toxicities of any grade attributable to RAPA-201, including no cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome. Only 4 of 14 patients (29%) had a serious adverse event (≥ grade 3) of any attribution. Conclusions Consistent with our hypothesis, ex vivo manufacturing using mTOR inhibition and IFN-α polarization consistently yielded a novel RAPA-201 DP that possessed a desirable phenotype relative to cytokine phenotype, memory status, and checkpoint expression. RAPA-201 recipients had preservation of T cell counts and Th1 cytokine secretion yet had increased T cell receptor clonality that associates with antitumor responses in the setting of monoclonal antibody checkpoint therapy. RAPA-201 therapy overcomes previous barriers to effective autologous polyclonal T-cell therapy, as it is feasible to manufacture, exquisitely safe to administer, and mediates remission in patients with RRMM. Trial registration number ClinicalTrials.gov: NCT04176380 .
Diagnostic accuracy of self-collected tongue swabs for Mycobacterium tuberculosis complex detection in individuals being assessed for TB in South Africa using the Xpert MTB/RIF Ultra assay
Authors: Anura David, Lyndel Singh, Keneilwe Peloakgosi-Shikwambani, Zanele Nsingwane, Violet Molepo, Gerard Cangelosi, Pedro da Silva, Wendy Stevens, Lesley Scott
Journal: Clinical Microbiology and Infection (2025)
B7-H3-Liquid Biopsy for the Characterization and Monitoring of the Dynamic Biology of Prostate Cancer
Authors: Yong Ju, Joshua Watson, Jasmine J Wang, Ying-Tzu Yen, Lilit Gevorkian, Zijing Chen, Kai Han Tu, Brenda Salumbides, Aaron Phung, Chen Zhao, Hyoyong Kim, You-Ren Ji, Ryan Y Zhang, Junseok Lee, Jun Gong, Kevin Scher, Sungyong You, Jie-Fu Chen, Hsian-Rong Tseng, Yazhen Zhu, Edwin M Posadas
Journal: Drug Resistance Updates (2025)
Longitudinal Associations of PFAS Exposure With Insulin Sensitivity and β-Cell Function Among Hispanic Women With Gestational Diabetes Mellitus History
Authors: Ni Kang, Wu Chen, Nosa Osazuwa, Chenyu Qiu, Julianne Cook Botelho, Antonia M. Calafat, Dean Jones, Thomas Buchanan, Anny H. Xiang, Zhanghua Chen
Journal: Diabetes Care (2025)

OBJECTIVE We investigated associations between per- and polyfluoroalkyl substances (PFAS) and changes in diabetes indicators from pregnancy to 12 years after delivery among women with a history of gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS Eighty Hispanic women with GDM history were followed from the third trimester of pregnancy to 12 years after delivery. Oral and intravenous glucose tolerance tests were conducted during follow-up. Plasma PFAS concentrations were measured at the third trimester of pregnancy and first postpartum visit. A linear mixed-effects model was used to analyze associations between PFAS and trajectories of diabetes indicators, adjusted for age, breastfeeding status, daily total calorie intake, and body fat percentage. RESULTS Increased 2-(N-methyl-perfluorooctane sulfonamido) acetate level was associated with faster increase in concentrations of fasting glucose (P = 0.003). Increased perfluorononanoate (PFNA) and linear perfluorooctanoate (n-PFOA) concentrations were associated with faster increase in fasting insulin concentrations (P = 0.04 for PFNA; P = 0.02 for n-PFOA) and faster decrease in acute insulin response to glucose (P = 0.04 for PFNA; P = 0.02 for n-PFOA). CONCLUSIONS PFAS exposure is associated with glucose intolerance, insulin resistance, and β-cell dysfunction, thus increasing type 2 diabetes risk.
Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion
Authors: Jin Soo Lee, Hyun Goo Kang, Seong Hwan Ahn, Tae-Jin Song, Dong-Ick Shin, Hee-Joon Bae, Chang Hun Kim, Sung Hyuk Heo, Jae-Kwan Cha, Yeong Bae Lee, Eung Gyu Kim, Man Seok Park, Hee-Kwon Park, Jinkwon Kim, Sungwook Yu, Heejung Mo, Sung Il Sohn, Jee Hyun Kwon, Jae Guk Kim, Young Seo Kim, Jay Chol Choi, Yang-Ha Hwang, Keun Hwa Jung, Soo-Kyoung Kim, Woo Keun Seo, Jung Hwa Seo, Joonsang Yoo, Jun Young Chang, Mooseok Park, Ji Sung Lee, Chun San An, Byoung Joo Gwag, Dennis W. Choi, Sun U. Kwon
Journal: JAMA Network Open (2025)

Importance Nelonemdaz selectively antagonizes the 2B subunit of the N -methyl- d -aspartate glutamate receptor and scavenges free radical species. Objective To evaluate whether nelonemdaz enhances the clinical outcomes of patients with acute ischemic stroke undergoing emergent reperfusion therapy. Design, Setting, and Participants This multicenter double-blind placebo-controlled randomized phase 3 trial (December 25, 2021, to June 30, 2023, in South Korea) recruited patients with acute ischemic stroke who met the following criteria: National Institutes of Health Stroke Scale score greater than or equal to 8, Alberta Stroke Program Early Computed Tomography score greater than or equal to 4, and endovascular thrombectomy within 12 hours after stroke onset. Intervention Patients were assigned in a 1:1 ratio to receive intravenous infusions of nelonemdaz twice a day for 5 days or a matching placebo. Main Outcomes and Measures The primary end point was a favorable shift in the modified Rankin scale (mRS) 12 weeks after stroke onset. The secondary end points included various composites of the mRS at 5 and 12 weeks, symptomatic intracranial hemorrhage, and infarct volume. Both intention-to-treat and per-protocol analyses were conducted. Results A total of 496 patients were enrolled across 24 Korean stroke centers, of whom 39 dropped out (254 men [55.6%]; mean [SD] age, 72.9 [12.1] years). Baseline characteristics of study participants did not significantly differ. For the primary end point, the distribution of the mRS scores at 12 weeks did not significantly differ between the nelonemdaz and placebo groups (common odds ratio, 0.95; 95% CI, 0.69-1.31). For the secondary end points, a median of mRS at 5 weeks (3 vs 3) and mRS 0 at 12 weeks (18.1% vs 18.2%) did not differ substantially between groups. The occurrence of symptomatic intracranial hemorrhage (2.7% vs 0.9%) and infarct volume within 24 hours of the last trial drug infusion (42 vs 38 mL) did not differ significantly between groups. No serious adverse events were reported regarding the trial drug and placebo. Conclusions and Relevance In this randomized clinical trial, nelonemdaz did not meet the primary efficacy end point compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT05041010
Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial
Authors: Stefano Barco, Houman Jalaie, Tim Sebastian, Simon Wolf, Riccardo M. Fumagalli, Michael Lichtenberg, Thomas Zeller, Christian Erbel, Oliver Schlager, Nils Kucher
Journal: Circulation (2025)

Background: In patients with post-thrombotic syndrome (PTS), stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial tested whether daily aspirin 100 mg plus rivaroxaban 20 mg is superior to rivaroxaban 20 mg alone to prevent stent thrombosis within 6 months after stent placement for PTS. Methods: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score &gt;4 points, a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein, successfully treated with venous stent placement, were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included age &lt;18 or &gt;75 years, contraindications to anticoagulant use or acute venous thrombosis &lt;3 months. The primary efficacy outcome was the composite of no occlusion in the treated segment assessed at serial duplex ultrasound examinations or no re-intervention needed to maintain patency within 6 months. Secondary outcomes, including Villalta score, quality of life, and safety outcomes were also assessed. The study was registered in ClinicalTrials.gov (NCT04128956). Results: From 2020 through 2022, 172 patients were screened, 169 randomized and 162 included in the full analysis set, receiving either aspirin plus rivaroxaban (n=80) or rivaroxaban alone (n=82) for six months. Mean age was 42.8 (standard deviation 14.7) years, 103 (60.9%) patients were women, 154 (97.5%) were Caucasian, and leg ulcers were present in 7% patients. The primary patency rate at six months was 94.8% vs. 92.4% (absolute risk difference: 2.4%; 95 %CI -13.6%; +18.0%), respectively. The mean decrease in the Villalta score for the affected leg (without ulcer) from baseline to 6 months was -6.7 (SD 4.4) and -7.0 (SD 5.2) points (p-value 0.36), respectively. There were no differences in other outcomes or quality of life at 6 months. No major bleeding occurred. Conclusions: The overall primary patency rate during the first six months following endovascular intervention for PTS was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban alone.
Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy
Authors: Andrew T Frisch, Yiyang Wang, Bingxian Xie, Aaron Yang, B Rhodes Ford, Supriya Joshi, Katarzyna M Kedziora, Ronal Peralta, Drew Wilfahrt, Steven J Mullett, Kellie Spahr, Konstantinos Lontos, Jessica A Jana, Victoria G Dean, William G Gunn, Stacy Gelhaus, Amanda C Poholek, Dayana B Rivadeneira, Greg M Delgoffe
Journal: Cell Metabolism (2025)
Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis
Authors: Xuqing Shen, Yueyue Chen, Yingying Tang, Ping Lu, Mingzhu Liu, Tiebo Mao, Yawen Weng, Feier Yu, Yimei Liu, Yujie Tang, Liwei Wang, Ningning Niu, Jing Xue
Journal: Cell Reports Medicine (2025)

Pancreatic ductal adenocarcinoma (PDAC) relies heavily on glutamine (Gln) utilization to meet its metabolic and biosynthetic needs. How epigenetic regulators contribute to the metabolic flexibility and PDAC's response and adaptation to Gln scarcity in the tumor milieu remains largely unknown. Here, we elucidate that prolonged Gln restriction or treatment with the Gln antagonist, 6-diazo-5-oxo-L-norleucine (DON), leads to growth inhibition and ferroptosis program activation in PDAC. A CRISPR-Cas9 screen identifies an epigenetic regulator, Paxip1, which promotes H3K4me3 upregulation and Hmox1 transcription upon DON treatment. Additionally, ferroptosis-related repressors (e.g., Slc7a11 and Gpx4) are increased as an adaptive response, thereby predisposing PDAC cells to ferroptosis upon Gln deprivation. Moreover, DON sensitizes PDAC cells to GPX4 inhibitor-induced ferroptosis, both in vitro and in patient-derived xenografts (PDXs). Taken together, our findings reveal that targeting Gln dependency confers susceptibility to GPX4-dependent ferroptosis via epigenetic remodeling and provides a combination strategy for PDAC therapy.
A functional cardiac patch promotes cardiac repair by modulating the CCR2− cardiac-resident macrophage niche and their cell crosstalk
Authors: Chengbin Ding, Guofeng Tang, Yan Sun, Xiaodong Fu, Ye Tian, Jiamian Zhan, Songtao Zhang, Xianglong Xing, Jianing Liu, Xiaozhong Qiu, Leyu Wang
Journal: Cell Reports Medicine (2025)

C-C chemokine receptor type 2 (CCR2-) cardiac-resident macrophages (CCR2- cRMs) are known to promote cardiac repair after myocardial infarction (MI). However, the substantial depletion and slow recovery of CCR2- cRMs pose significant barriers in cardiac recovery. Here, we construct a functional conductive cardiac patch (CCP) that can provide exogenously elastic conductive microenvironment and induce endogenously reparative microenvironment mediated by CCR2- cRMs for MI repair. This CCP exhibits suitable mechanical properties, conductivity, and high water retention, reminiscent of natural myocardium, which can actively engage in modulating CCR2- cRM renewal and their cell crosstalk. The functional CCP can promote the expression of Connexin43 between CCR2- cRMs and cardiomyocytes (CMs) and regulate paracrine signaling to activate epicardial cell epithelial-to-mesenchymal transition (EMT) toward endothelial cells using rat and Wt1CreERT2 transgenic lineage tracing mice. Overall, this study provides a promising strategy to construct a synergistic reparative microenvironment for MI repair.
Muscle-derived small extracellular vesicles induce liver fibrosis during overtraining
Authors: Ya Liu, Rui Zhou, Yifan Guo, Biao Hu, Lingqi Xie, Yuze An, Jie Wen, Zheyu Liu, Min Zhou, Weihong Kuang, Yao Xiao, Min Wang, Genqing Xie, Haiyan Zhou, Renbin Lu, Hui Peng, Yan Huang
Journal: Cell Metabolism (2025)
Projection-targeted photopharmacology reveals distinct anxiolytic roles for presynaptic mGluR2 in prefrontal- and insula-amygdala synapses
Authors: Hermany Munguba, Ipsit Srivastava, Vanessa A Gutzeit, Ashna Singh, Akshara Vijay, Melanie Kristt, Anisul Arefin, Sonal Thukral, Johannes Broichhagen, Joseph M Stujenske, Conor Liston, Joshua Levitz
Journal: Neuron (2025)
Latest clinical frontiers related to autism diagnostic strategies
Authors: Samuele Cortese, Alessio Bellato, Alessandra Gabellone, Lucia Marzulli, Emilia Matera, Valeria Parlatini, Maria Giuseppina Petruzzelli, Antonio M Persico, Richard Delorme, Paolo Fusar-Poli, Corentin J Gosling, Marco Solmi, Lucia Margari
Journal: Cell Reports Medicine (2025)
Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut
Authors: Yifei Zhang, Ruixin Liu, Yufei Chen, Zhiwen Cao, Cong Liu, Riqiang Bao, Yufan Wang, Shan Huang, Shijia Pan, Li Qin, Jiqiu Wang, Guang Ning, Weiqing Wang
Journal: Cell Metabolism (2025)
A cis-regulatory element controls expression of histone deacetylase 9 to fine-tune inflammasome-dependent chronic inflammation in atherosclerosis
Authors: Yaw Asare, Guangyao Yan, Christina Schlegl, Matthias Prestel, Emiel P C van der Vorst, Abraham J P Teunissen, Arailym Aronova, Federica Tosato, Nawraa Naser, Julio Caputo, Geoffrey Prevot, Anthony Azzun, Benedikt Wefers, Wolfgang Wurst, Melanie Schneider, Ignasi Forne, Kiril Bidzhekov, Ronald Naumann, Sander W van der Laan, Markus Brandhofer, Jiayu Cao, Stefan Roth, Rainer Malik, Steffen Tiedt, Willem J M Mulder, Axel Imhof, Arthur Liesz, Christian Weber, Jürgen Bernhagen, Martin Dichgans
Journal: Immunity (2025)

Common genetic variants in a conserved cis-regulatory element (CRE) at histone deacetylase (HDAC)9 are a major risk factor for cardiovascular disease, including stroke and coronary artery disease. Given the consistency of this association and its proinflammatory properties, we examined the mechanisms whereby HDAC9 regulates vascular inflammation. HDAC9 bound and mediated deacetylation of NLRP3 in the NACHT and LRR domains leading to inflammasome activation and lytic cell death. Targeted deletion of the critical CRE in mice increased Hdac9 expression in myeloid cells to exacerbate inflammasome-dependent chronic inflammation. In human carotid endarterectomy samples, increased HDAC9 expression was associated with atheroprogression and clinical plaque instability. Incorporation of TMP195, a class IIa HDAC inhibitor, into lipoprotein-based nanoparticles to target HDAC9 at the site of myeloid-driven vascular inflammation stabilized atherosclerotic plaques, implying a lower risk of plaque rupture and cardiovascular events. Our findings link HDAC9 to atherogenic inflammation and provide a paradigm for anti-inflammatory therapeutics for atherosclerosis.
The meninges host a distinct compartment of regulatory T cells that preserves brain homeostasis
Authors: Miguel Marin-Rodero, Elisa Cintado, Alec J. Walker, Teshika Jayewickreme, Felipe A. Pinho-Ribeiro, Quentin Richardson, Ruaidhrí Jackson, Isaac M. Chiu, Christophe Benoist, Beth Stevens, José Luís Trejo, Diane Mathis
Journal: Science Immunology (2025)

Our understanding of the meningeal immune system has recently burgeoned, particularly regarding how innate and adaptive effector cells are mobilized to meet brain challenges. However, information on how meningeal immunocytes guard brain homeostasis in healthy individuals remains limited. This study highlights the heterogeneous, polyfunctional regulatory T cell (T reg ) compartment in the meninges. A T reg subtype specialized in controlling interferon-gamma (IFN-γ) responses and another dedicated to regulating follicular B cell responses were substantial components of this compartment. Accordingly, punctual T reg ablation rapidly unleashed IFN-γ production by meningeal lymphocytes, unlocked access to the brain parenchyma, and altered meningeal B cell profiles. Distally, the hippocampus assumed a reactive state, with morphological and transcriptional changes in multiple glial cell types. Within the dentate gyrus, neural stem cells underwent more death and were blocked from further differentiation, which coincided with impairments in short-term spatial-reference memory. Thus, meningeal T regs are a multifaceted safeguard of brain homeostasis at steady state.
Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer
Authors: Van K. Morris, Weihong Xiao, Kangyu Lin, Chi Wut Wong, Michael T. Wotman, Emma B. Holliday, Ryan W. Huey, Sonal S. Noticewala, Ethan B. Ludmir, Alisha H. Bent, Kaysia Ludford, Craig Messick, Eugene J. Koay, Grace Smith, Tsuyoshi Konishi, Brian Bednarski, George J. Chang, Albert C. Koong, Y. Nancy You, Prajnan Das, Maura L. Gillison
Journal: Clinical Cancer Research (2025)

Abstract Background: While detection of circulating tumor DNA (ctDNA) weeks after surgery is linked to recurrence for other solid tumors, the optimal time point for ctDNA assessment as a prognostic biomarker following chemoradiation for anal cancer is undefined. Methods: Patients with stages I-III anal cancer treated with chemoradiation between 12/2020-5/2024 were evaluated for HPV ctDNA status at baseline, at the end of chemoradiation, and during surveillance using a droplet digital HPV ctDNA PCR assay targeting HPV E6 and E7 oncogenes for 13 oncogenic HPV types. Median recurrence-free survival (RFS) according to HPV ctDNA status was estimated via Kaplan-Meier and compared using a log-rank test. Results: Detection of HPV ctDNA at ≥3 months after chemoradiation was associated with recurrence (80% versus 2%; odds ratio 168, 95% CI 13.6-2080; p&amp;lt;.0001) and inferior RFS (4.9 months versus not reached (NR); hazard ratio (HR) 39.2, 95% CI 4.6-330; p&amp;lt;.0001) relative to HPV ctDNA-negative status. Sensitivity and specificity for recurrence according to HPV ctDNA detection were 89% and 95%, respectively, with positive and negative predictive values of 80% and 98%, respectively. Differences in RFS according to HPV ctDNA status were not observed at the end of treatment (median RFS NR for both; HR 1.6, 95% CI .35-7.4; p=.48). Conclusions: With a novel, highly sensitive assay, detection of HPV ctDNA at least 3 months after chemoradiation was associated with unfavorable survival. Future clinical trials should incorporate this 3-month post-treatment time point to identify patients with HPV-positive anal cancer at elevated recurrence risk according to HPV ctDNA status.
Advances in systematic conservation planning to meet global biodiversity goals
Authors: Sylvaine Giakoumi, Anthony J Richardson, Aggeliki Doxa, Stefano Moro, Marco Andrello, Jeffrey O Hanson, Virgilio Hermoso, Tessa Mazor, Jennifer McGowan, Heini Kujala, Elizabeth Law, Jorge G Álvarez-Romero, Rafael A Magris, Elena Gissi, Nur Arafeh-Dalmau, Anna Metaxas, Elina A Virtanen, Natalie C Ban, Robert M Runya, Daniel C Dunn, Simonetta Fraschetti, Ibon Galparsoro, Robert J Smith, Francois Bastardie, Vanessa Stelzenmüller, Hugh P Possingham, Stelios Katsanevakis
Journal: Trends in Ecology & Evolution (2025)